MET exon 14 mutations in Non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression

Journal of Clinical Oncology

Volumn 34, Issue 7, 2016, Pages 721-730

  Awad, Mark M ^a,b   Oxnard, Geoffrey R ^a,b   Jackman, David M ^a,b   Savukoski, Daniel O ^b   Hall, Dimity ^b   Shivdasani, Priyanka ^b   Heng, Jennifer C ^a   Dahlberg, Suzanne E ^a   Jänne, Pasi A ^a,b   Verma, Suman ^c   Christensen, James ^d   Hammerman, Peter S ^a,b   Sholl, Lynette M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ResearchDx   (United States)

^d METHYLGENE INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; SCATTER FACTOR RECEPTOR; MET PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CASE REPORT; CHROMOSOME 7; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; AGE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; EXON; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PATHOLOGY; RISK FACTOR; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; EXONS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 84964388926     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.4600     Document Type: Article

References (47)

1. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
2. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
3. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311, 2004
4. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
5. Shaw AT, Kim DW, Mehra R, et al: Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370:1189-1197, 2014
6. Seto T, Kiura K, Nishio M, et al: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1-2 study. Lancet Oncol 14:590-598, 2013
7. Shaw AT, Ou SH, Bang YJ, et al: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963-1971, 2014
8. Davies KD, Le AT, Theodoro MF, et al: Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18:4570-4579, 2012
9. Jenkins RW, Oxnard GR, Elkin S, et al: Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. Clin Lung Cancer 16:e101-e104, 2015
10. Waqar SN, Morgensztern D, Sehn J: MET mutation associated with responsiveness to crizotinib. J Thorac Oncol 10:e29-e31, 2015
11. Mendenhall MA, Goldman JW: MET-mutated NSCLC with major response to crizotinib. J Thorac Oncol 10:e33-e34, 2015
12. Frampton GM, Ali SM, Rosenzweig M, et al: Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5:850-859, 2015
13. Paik PK, Drilon A, Fan PD, et al: Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 5:842-849, 2015
14. Camidge DR, Ou S-HI, Shapiro G, et al: Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 32:506s, 2014(suppl; abstr 8001)
15. Sakai K, Aoki S, Matsumoto K: Hepatocyte growth factor and Met in drug discovery. J Biochem 157:271-284, 2015
16. Peschard P, Fournier TM, Lamorte L, et al: Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8:995-1004, 2001
17. Ma PC, Jagadeeswaran R, Jagadeesh S, et al: Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65:1479-1488, 2005
18. Kong-Beltran M, Seshagiri S, Zha J, et al: Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66:283-289, 2006
19. MacConaill LE, Garcia E, Shivdasani P, et al: Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn 16:660-672, 2014
20. Wagle N, Berger MF, Davis MJ, et al: Highthroughput detection ofactionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2:82-93, 2012
21. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285, 2011
22. Travis WD, Brambilla E, Müller-Hermelink HK, et al: WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (ed 4). Lyon, France, International Agency for Research on Cancer, 2004
23. Gruver AM, Liu L, Vaillancourt P, et al: Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET). Histopathology 65:879-896, 2014
24. Sholl LM, Weremowicz S, Gray SW, et al: Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 8:322-328, 2013
25. Cutz JC, Craddock KJ, Torlakovic E, et al: Canadian anaplastic lymphoma kinase study: A model for multicenter standardization and optimization of ALK testing in lung cancer. J Thorac Oncol 9:1255-1263, 2014
26. Sholl LM, Sun H, Butaney M, et al: ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol 37:1441-1449, 2013
27. Liu X, Jia Y, Stoopler MB, et al: Nextgeneration sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol doi:JCO. 2015. 62. 0674
28. Human Protein Reference Database. Hepatocyte growth factor receptor. http://www.hprd.org/summary?hprd-id=01280&isoform-id=01280-2&isoform-name=Isoform-1
29. Oliner JD, Kinzler KW, Meltzer PS, et al: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83, 1992
30. Bergethon K, Shaw AT, Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870, 2012
31. Lipson D, Capelletti M, Yelensky R, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18:382-384, 2012
32. Kohno T, Ichikawa H, Totoki Y, et al: KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18:375-377, 2012
33. Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381, 2012
34. Wang R, Hu H, Pan Y, et al: RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 30:4352-4359, 2012
35. Vaishnavi A, Capelletti M, Le AT, et al: Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 19:1469-1472, 2013
36. Rodig SJ, Mino-Kenudson M, Dacic S, et al: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15:5216-5223, 2009
37. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253, 2009
38. Paik PK, Arcila ME, Fara M, et al: Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29:2046-2051, 2011
39. Cardarella S, Ogino A, Nishino M, et al: Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 19:4532-4540, 2013
40. Yendamuri S, Caty L, Pine M, et al: Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. Surgery 152:397-402, 2012
41. Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543-550, 2014
42. [Erratum: Nature 514:262, 2014]
43. Onozato R, Kosaka T, Kuwano H, et al: Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 4:5-11, 2009
44. Satokata I, Tanaka K, Yuba S, et al: Identification of splicing mutations of the last nucleotides of exons, a nonsense mutation, and a missense mutation of the XPAC gene as causes of group A xeroderma pigmentosum. Mutat Res 273:203-212, 1992
45. Kanai N, Yanai F, Hirose S, et al: A G to A transition at the last nucleotide of exon 6 of the gamma c gene (868G-. A) may result in either a splice or missense mutation in patients with X-linked severe combined immunodeficiency. Hum Genet 104:36-42, 1999
46. Ozkara HA, Sandhoff K: A new point mutation (G412 to A) at the last nucleotide of exon 3 of hexosaminidase alpha-subunit gene affects splicing. Brain Dev 25:203-206, 2003
47. Lovly CM, Shaw AT: Molecular pathways: Resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res 20:2249-2256, 2014